The Food and Drug Administration (FDA) has approved Otarmeni (lunsotogene parvec-cwha), the first gene therapy designed to treat genetic hearing loss. This groundbreaking treatment utilizes a dual adeno-associated virus (AAV) vector system, employing two harmless viruses to deliver the therapeutic agent.
Clinical trials demonstrated that Otarmeni improved hearing in patients with OTOF-related deafness. The therapy targets severe to profound hearing loss caused by mutations in the OTOF gene, enabling natural acoustic hearing. This marks the first disease-modifying treatment for OTOF-related deafness.
Administered surgically as a one-time treatment directly into the inner ear, Otarmeni delivers a healthy copy of the OTOF gene. This restores the otoferlin protein, crucial for sending auditory signals to the brain. Potential side effects include middle ear infection, nausea, dizziness, and procedural pain.